This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Prophylaxis On-Demand Bleed Control Dosing options Clinical History Important Safety Information Abbreviated Prescribing Information

This site is intended only for healthcare professionals resident in [country]




Sign InLog Out
Our medicinesOur medicines

See the global brands that have PfizerPro content ready for cloning to your local market. You can see the full list of available global brands here

Featured medicinesEnbrelIbranceNgenlaPaxlovidPrevenar 13TalzennaVyndaqelXeljanzExample BlueprintsBrand BlueprintTherapy Area BlueprintSplash Page Blueprint​​​​​​​
Therapy areasExplore contentExplore content

Example of description text sitting alongside header

EventsDownloadable materialsVideos
Let’s connectLet's Connect

Example of description text sitting alongside header

Contact usAsk a questionPfizer medical informationSign up to our newsletter
Important Safety Information

Indications: Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency). BeneFIX can be used for all age groups.1

DosingDose and duration of the substitution therapy depend on the severity of the factor IX deficiency, on the location and extent of bleeding, and on the patient’s clinical condition. The number of units of factor IX administered is expressed in IU.1

On demand treatmentThe calculation of the required dose of BeneFIX can be based on the finding that one unit of factor IX activity per kg body weight is expected to increase the circulating level of factor IX, an average of 0.8 IU/dL (range from 0.4 to 1.4 IU/dL) in patients ≥ 12 years.1

Prophylaxis: BeneFIX may be administered for long term prophylaxis against bleeding in patients with severe haemophilia B. In a clinical study for routine secondary prophylaxis the average dose for PTPs was 40 IU/kg (range 13 to 78 IU/kg) at intervals of 3 to 4 days.1

Contraindications: Hypersensitivity to the active substance or to any of the excipients. Known allergic reaction to hamster proteins.1

Special warnings and precautions for useAllergic-type hypersensitivity reactions are possible with BeneFIX. In patients with existing cardiovascular risk factors, substitution therapy with FIX may increase the cardiovascular risk. Inhibitors are an uncommon event in PTPs receiving factor IX-containing products. Because of the potential risk of thrombotic complications, clinical surveillance for early signs of thrombotic and consumptive coagulopathy should be initiated with appropriate biological testing when administering this product to patients with liver disease, to patients post-operatively, to new-born infants, or to patients at risk of thrombotic phenomena or DIC.1

Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Patients can affix one of the peel-off labels found on the vial to document the batch number in their diary or for reporting any side effects.1

Special populations: Sufficient data have not been obtained from clinical studies on the treatment of previously untreated patients (PUPs) with BeneFIX.1

Fertility, pregnancy and lactation: Animal reproduction studies have not been conducted with factor IX. Based on the rare occurrence of haemophilia B in women, experience regarding the use of factor IX during pregnancy and breastfeeding is not available. Therefore, factor IX should be used during pregnancy and breast-feeding only if clearly indicated. The effect of BeneFIX on fertility has not been established.1

Effects on ability to drive and use machines: BeneFIX has no influence on the ability to drive or use machines.1

Adverse reactions: Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) have been observed and may in some cases progress  to severe anaphylaxis (including shock).Patients with haemophilia B may develop neutralising antibodies (inhibitors) to factor IX. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. There is a potential risk of thromboembolic episodes following the administration of factor IX products.1

Very Common (≥ 1/10): Headache, cough and pyrexia1

Common (≥ 1/100 to < 1/10): Hypersensitivity, dizziness, dysgeusia, phlebitis, flushing, vomiting, nausea, rash, urticaria, chest discomfort, infusion-site reaction and infusion-site pain.1

DIC: disseminated intravascular coagulation; FIX: factor IX; IU: international unit; PTP: previously treated patient.


  1. Benefix Egyptian Drug Authority leaflet approval date: 14/11/2021. Revision Date: November 2020.

Approval No. : BV0098A2259/032022

Invalidation Date: 17/02/2025

Benefix Homepage

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No